New research indicates that oral drugs related to semaglutide, similar to medications like Ozempic, may reduce pleasure-driven eating by impacting a key brain circuit. The study, conducted on mice, suggests potential implications for understanding and treating food cravings as well as substance use disorder.
The study revealed that newer oral drugs connected to semaglutide reduced pleasure-driven eating in mice. Researchers found the medications quieted a deep brain reward circuit, suggesting a neurological mechanism behind decreased cravings. The findings were recently published by ScienceDaily.
The research team’s work could open new avenues for understanding how food cravings develop and potentially offer novel treatment strategies. Importantly, the study also suggests that targeting this same brain circuitry might be beneficial in addressing substance use disorder, as both conditions involve reward pathways in the brain. The precise mechanisms are still being investigated, but the initial results point to a promising area of research.
Wir bewerten keine Wahrheit. Wir entfernen den Spin und zeigen Ihnen, welche Perspektiven die Geschichte abgedeckt haben. Sie entscheiden.
Originale Berichterstattung lesen
💬 Kommentare
📜 Kommentar-Richtlinie